Single-Cell Transcriptomics Reveals a Multi-Compartmental Cellular Cascade Underlying Elahere-Induced Ocular Toxicity in Rats
Open Access
- 4 October 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (10) , 1492
Abstract
Background: Antibody-drug conjugates (ADCs) have ushered in a new era of precision oncology by combining the targeting specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic drugs. However, the cellular and molecular mechanisms underlying their dose-limiting ocular toxicity remain unclear. Elahere™, the first FDA-approved ADC targeting folate receptor α (FRα), demonstrates remarkable efficacy in platinum-resistant ovarian cancer but causes keratitis and other ocular toxicities in some patients. Notably, FRα is not expressed in the corneal epithelium—the primary site of damage—highlighting the urgent need to elucidate its underlying mechanisms. The aim of this study was to identify the cell-type-specific molecular mechanisms underlying Elahere-induced ocular toxicity. Methods: Sprague-Dawley rats were treated with intravenous Elahere (20 mg/kg) or vehicle weekly for five weeks. Ocular toxicity was determined by clinical examination and histopathology. Corneal single-cell suspensions were analyzed using the BD Rhapsody single-cell RNA sequencing (scRNA-seq) platform. Bioinformatic analyses to characterize changes in corneal cell populations, gene expression, and signaling pathways included cell clustering, differential gene expression, pseudotime trajectory inference, and cell-cell interaction modeling. Results: scRNA-seq profiling of 47,606 corneal cells revealed significant damage to the ocular surface and corneal epithelia in the Elahere group. Twenty distinct cell types were identified. Elahere depleted myeloid immune cells; in particular, homeostatic gene expression was suppressed in phagocytic macrophages. Progenitor populations (limbal stem cells and basal cells) accumulated (e.g., a ~2.6-fold expansion of limbal stem cells), while terminally differentiated cells decreased in corneal epithelium, indicating differentiation blockade. Endothelial cells exhibited signs of injury and inflammation, including reduced angiogenic subtypes and heightened stress responses. Folate receptor alpha, the target of Elahere, was expressed in endothelial and stromal cells, potentially driving stromal cells toward a pro-fibrotic phenotype. Fc receptor genes were predominantly expressed in myeloid cells, suggesting a potential mechanism underlying their depletion. Conclusions: Elahere induces complex, multi-compartmental ocular toxicity characterized by initial perturbations in vascular endothelial and immune cell populations followed by the arrest of epithelial differentiation and stromal remodeling. These findings reveal a cascade of cellular disruptions and provide mechanistic insights into mitigating Elahere-associated ocular side effects.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFC3404004)
This publication has 39 references indexed in Scilit:
- Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs)Current Ophthalmology Reports, 2024
- Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2023
- A pan-cancer single-cell panorama of human natural killer cellsCell, 2023
- Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansineGynecologic Oncology Reports, 2023
- Bacterial droplet-based single-cell RNA-seq reveals antibiotic-associated heterogeneous cellular statesCell, 2023
- Single‐cell RNA sequencing technologies and applications: A brief overviewClinical and Translational Medicine, 2022
- Single-cell RNA sequencing: Technical advancements and biological applicationsMolecular Aspects of Medicine, 2018
- Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter DropletsCell, 2015
- Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug ConjugatesPharmaceutical Research, 2014
- Antibody–drug conjugates: targeted drug delivery for cancerCurrent Opinion in Chemical Biology, 2010